These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25535100)

  • 21. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
    Sheng W; Kirschner-Hermanns R; Zhang H
    World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse Features and Competing Risk Mortality in Patients With High-Risk Prostate Cancer.
    Vagnoni V; Bianchi L; Borghesi M; Pultrone CV; Dababneh H; Chessa F; La Manna G; Rizzi S; Porreca A; Brunocilla E; Martorana G; Schiavina R
    Clin Genitourin Cancer; 2017 Apr; 15(2):e239-e248. PubMed ID: 27641658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
    Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
    Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
    Prostate; 2022 May; 82(6):740-750. PubMed ID: 35226380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
    Boehm K; Leyh-Bannurah SR; Rosenbaum C; Brandi LS; Budäus L; Graefen M; Huland H; Haferkamp A; Tilki D
    BJU Int; 2017 Nov; 120(5):666-672. PubMed ID: 28437038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality.
    Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Horlemann B; Tian Z; Saad F; Briganti A; Shariat SF; Gallucci M; Suardi N; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    Cancer Causes Control; 2022 May; 33(5):769-777. PubMed ID: 35230576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer.
    Milonas D; Ruzgas T; Venclovas Z; Jonusaite D; Matijosaitis AJ; Trumbeckas D; Varpiotas E; Auskalnis S; Skaudickas D; Mickevicius R; Vaiciunas K; Mickevicius J; Jievaltas M
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
    Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
    BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions.
    Gandaglia G; Tilki D; Zaffuto E; Fossati N; Pompe RS; Dell'Oglio P; Graefen M; Montorsi F; Briganti A
    Eur Urol Focus; 2019 Jul; 5(4):545-549. PubMed ID: 29153885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.
    Gandaglia G; Karakiewicz PI; Abdollah F; Becker A; Roghmann F; Sammon JD; Kim SP; Perrotte P; Briganti A; Montorsi F; Trinh QD; Sun M
    Eur J Surg Oncol; 2014 Dec; 40(12):1706-15. PubMed ID: 24915856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.
    Sivaraman A; Ordaz Jurado G; Cathelineau X; Barret E; Dell'Oglio P; Joniau S; Bianchi M; Briganti A; Spahn M; Bastian P; Chun J; Chlosta P; Gontero P; Graefen M; Jeffrey Karnes R; Marchioro G; Tombal B; Tosco L; van der Poel HH; Sanchez-Salas R
    World J Urol; 2016 Oct; 34(10):1367-72. PubMed ID: 26897499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer.
    Dell'Oglio P; Zaffuto E; Boehm K; Trudeau V; Larcher A; Tian Z; Moschini M; Shariat SF; Graefen M; Saad F; Capitanio U; Briganti A; Montorsi F; Karakiewicz PI
    Eur J Surg Oncol; 2017 Aug; 43(8):1581-1588. PubMed ID: 28330822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Sundi D; Tosoian JJ; Nyame YA; Alam R; Achim M; Reichard CA; Li J; Wilkins L; Schwen Z; Han M; Davis JW; Klein EA; Schaeffer EM; Stephenson AJ; Ross AE; Chapin BF
    Cancer; 2019 Feb; 125(3):391-397. PubMed ID: 30423193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
    Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
    Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
    Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.